

**Table S1** ICIs regimen of postoperative recurrent non-small cell lung cancer without EGFR mutations or ALK rearrangements

Variable	ICI use in clinical course (N=79), n [%]	
	1st line (N=54)	2nd line or later (N=25)
Combination with cytotoxic chemotherapy		
Yes	29 [54]	0
No	25 [46]	25 [100]
ICIs regimen		
Pembrolizumab	45 [83]	7 [28]
Atezolizumab	7 [13]	7 [28]
Nivolumab	1 [2]	11 [44]
Ipilimumab	1 [2]	0

ICI, immune checkpoint inhibitor; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoid kinase.